PF 232798

Drug Profile

PF 232798

Alternative Names: PF-00232798; PF-232798

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; ViiV Healthcare
  • Class Antivirals; Imidazoles; Piperidines
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 17 Jun 2015 Discontinued - Phase-I for HIV infections (In volunteers) in Singapore (PO)
  • 17 Jun 2015 Discontinued - Phase-II for HIV infections in Germany (PO)
  • 22 Dec 2010 Pfizer & ViiV Healthcare complete a phase I trial in Healthy volunteers in Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top